Antiplatelet therapy for every diabetic person? - Wikidata - awgldk - TriplyDB

Antiplatelet therapy for every diabetic person?

Antiplatelet therapy for every diabetic person?

http://www.wikidata.org/entity/Q36783726

about

Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial Refining Long-Term Prediction of Cardiovascular Risk in Diabetes - The VILDIA Score.Achievement of cardiometabolic goals among diabetic patients in Spain. A nationwide population-based study.Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.Disordered haematopoiesis and athero-thrombosis.Metformin use among individuals at risk for type 2 diabetes.Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.Platelets, diabetes and myocardial ischemia/reperfusion injury.Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control.

P2860

Q28481709-527F2E78-E9BA-4F0E-BABB-8F08B4E56207 Q33875341-ECB44175-9E42-4E31-B730-6831EE491BCF Q34700385-43C83CEE-3251-4F43-AC40-59C02176DC48 Q35991934-AEAA0C37-383F-472B-A229-4BD8CCDCE026 Q36773876-C284C765-3EC4-4BFE-ADA6-4987501B7489 Q37991589-7536DA5F-585B-4A8D-A00A-E6E28EB86259 Q38003113-38A1E66D-9EED-4963-B380-C7E83C41B9FB Q39343342-EB11FBDB-BB18-4FC9-ADE1-928BCEB0F55D Q42180113-16F9BFFE-D136-4789-A2D2-5C6A3FA834AD Q47727795-F5BD73F8-FB20-45EA-923F-82B14677B8B6

P2860

Antiplatelet therapy for every diabetic person?

http://www.wikidata.org/entity/Q36783726

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Antiplatelet therapy for every diabetic person?

@en

type

label

Antiplatelet therapy for every diabetic person?

@en

prefLabel

Antiplatelet therapy for every diabetic person?

@en

P1433

Q36783726-3A8B9926-31A9-441F-8D28-0DDD5AF57F9A

P1476

Q36783726-AEC0C36D-4154-4576-9C0E-E02B88876188

P2093

Q36783726-6514EB68-FC08-41E2-99B6-9B46EC241AD6

Q36783726-9B726A1A-F2D2-4AC6-B5FF-D2EB5E98A5F1

P2860

Q36783726-0B9E9138-243D-4DD4-A403-02E48F7D2FE9

Q36783726-0D846769-8B9D-4E52-9A6D-5364B32A7031

Q36783726-21A5047F-2D88-49C6-9A40-54238ACD94BA

Q36783726-24CBD9EB-F305-46ED-BE22-478A8CBE08D3

Q36783726-2BA02D8D-1EC3-42BB-A609-7921FB1249FD

Q36783726-2D917747-AEE6-4796-96F3-56C77F6A04FA

Q36783726-30B2BEA2-339F-4E5B-BA30-02757F7D627B

Q36783726-3957A739-B083-4E80-8A6B-6507327AD432

Q36783726-3E0B9C5D-68A4-4E35-AED3-2D79E3755E71

Q36783726-43748309-6058-4799-B8DB-90A8A1E807A3

P304

Q36783726-CFE5B933-E1EA-49FB-B414-1D3E4A8242B8

P31

Q36783726-1634B5FA-3637-4C02-82B5-60AEC631C285

P356

Q36783726-B5739B6C-A1EE-4B8A-A213-A5DE564E12F4

P407

Q36783726-05F1E6D8-8EFF-4000-AEDE-7DA282578793

P478

Q36783726-004331BA-9C9D-4CD7-8A3E-1C02E256BF32

P577

Q36783726-95A10439-AE0A-4BEA-BFB6-C1918E0FD5BD

P5875

Q36783726-725F9D0B-8A0E-412F-9788-B3032351AC93

P698

Q36783726-56489A73-E4D6-42B9-BDEB-B1A51015A8E6

P932

Q36783726-E0DBADEC-1A1A-4E31-BB29-AB940348AA3F

P356

P1433

P1476

Antiplatelet therapy for every diabetic person?

@en

P2093

Antonio Nicolucci

http://www.w3.org/2001/XMLSchema#string

Eberhard Standl

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions

P304

S150-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-S210

http://www.w3.org/2001/XMLSchema#string

P407

P478

34 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51082106

http://www.w3.org/2001/XMLSchema#string

P698

21525447

http://www.w3.org/2001/XMLSchema#string

P932

3632153

http://www.w3.org/2001/XMLSchema#string